Two years outcome of women infected with high risk HPV having normal colposcopy following low-grade or equivocal cytological abnormalities: Are HPV16 and 18 viral load clinically useful predictive markers?

Journal of Medical Virology

Volumn 84, Issue 6, 2012, Pages 964-972

  Carcopino, Xavier ^a,b,c   Henry, Mireille ^d   Mancini, Julien ^b,d   Giusiano, Sophie ^a,b   Boubli, Léon ^a,b   Olive, Daniel ^b,c   Tamalet, Catherine ^b,d  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

Cervical intraepithelial neoplasia; Colposcopy; Diagnosis; Human papillomavirus; Viral load

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; COLPOSCOPY; CYTOLOGY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION RISK; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PATHOGEN CLEARANCE; POPULATION RESEARCH; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; VAGINAL INTRAEPITHELIAL NEOPLASIA; VIRAL CLEARANCE; VIRUS LOAD; WART VIRUS;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 84859772491     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23276     Document Type: Article

References (35)

1. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. 2006. Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses. Vaccine 24: S78- S89.
2. Arbyn M, Kyrgiou M, Simoens C, Raifu AO, Koliopoulos G, Martin-Hirsch P, Prendiville W, Paraskevaidis E. 2008. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: Meta-analysis. BMJ 337: a1284.
3. Bulk S, Bulkmans NW, Berkhof J, Rozendaal L, Boeke AJ, Verheijen RH, Snijders PJ, Meijer CJ. 2007. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int J Cancer 121: 361- 367.
4. Carcopino X, Henry M, Benmoura D, Fallabregues AS, Richet H, Boubli L, Tamalet C. 2006. Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy. J Med Virol 78: 1131- 1140.
5. Carcopino X, Henry M, Olive D, Boubli L, Tamalet C. 2011. Detection and quantification of human papillomavirus genital infections: Virological, epidemiological, and clinical applications. Med Mal Infect 41: 68- 79.
6. Cox JT, Schiffman M, Solomon D. ASCUS-LSIL Triage Study (ALTS) Group. 2003. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 188: 1406- 1412.
7. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. 2003. Management of women who test positive for high-risk types of human papillomavirus: The HART study. Lancet 362: 1871- 1876.
8. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C. 2003. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. Int J Cancer 106: 396- 403.
9. Dillner J, Rebolj M, Birembaut P, Petry KU, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T. 2008. Long term predictive value of cytology and human papillomavirus testing in cervical cancer screening: Joint European cohort study. BMJ 337: a1754.
10. Gage JC, Schiffman M, Solomon D, Wheeler CM, Castle PE. 2010. Comparison of measurements of human papillomavirus persistence for postcolposocpic surveillance for cervical precancerous lesions. Cancer Epidemiol Biomarkers Prev 19: 1668- 1674.
11. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423- 428.
12. Jeronimo J, Schiffman M. 2006. Colposcopy at crossroads. Am J Obstet Gynecol 195: 349- 353.
13. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. 2006. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 367: 489- 498.
14. Lai CH, Chao A, Chang CJ, Chao FY, Huang HJ, Hsueh S, Lin CT, Cheng HH, Huang CC, Yang JE, Wu TI, Chou HH, Chang TC. 2008. Host and viral factors in relation to clearance of human papillomavirus infection: A cohort study in Taiwan. Int J Cancer 123: 1685- 1692.
15. Luesley D, Downey G. 2009. Value of normal colposocpy after abnormal cervical smear report. J Low Gen Tract Dis 13: 33- 37.
16. Marks M, Gravitt PE, Utaipat U, Gupta SB, Liaw K, Kim E, Tadesse A, Phongnarisorn C, Wootipoom V, Yuenyao P, Vipupinyo C, Rugpao S, Sriplienchan S, Celentano DD. 2011. Kinetics of DNA load predict HPV 16 viral clearance. J Clin Virol 51: 44- 49.
17. Maucort-Boulch D, Plummer M, Castle PE, Demuth F, Safaeian M, Wheeler CM, Schiffman M. 2010. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 126: 684- 691.
18. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R. 1998. Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis. Obstet Gynecol 91: 626- 631.
19. Munoz N, Castellsagne X, Berrington de Gonzalez, Gissmann L. 2006. HPV in the etiology of human cancer. Vaccine 53: S3/1- S3/10.
20. Munoz N, Hernandez-Suarez G, Mendez F, Molano M, Posso H, Moreno V, Murillo R, Ronderos M, Meijer C, Munoz A. 2009. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 100: 1184- 1190.
21. Nielsen A, Kjaer SK, Munk C, Osler M, Iftner T. 2010. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol 82: 616- 623.
22. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ. 1999. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: A prospective study. Lancet 354: 20- 25.
23. Pretet JL, Jacquard AC, Saunier M, Clavel C, Dachez R, Gondry J, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, Riethmuller D. 2008. Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2/3 and invasive cervical cancer: The EDiTH III study. Gynecol Oncol 110: 179- 184.
24. Pretorius RG, Peterson P, Azizi F, Burchette RJ. 2006. Subsequent risk and presentation of cervical intraepithelial neoplsai (CIN) 3 or cancer after a colposcopic diagnosis of CIN1 or less. Am J Obstet Gynecol 195: 1260.
25. Ramanakumar AV, Goncalves O, Richardson H, Tellier P, Ferenczy A, Coutlee F, Franco EL. 2010. Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect Dis 10: 326.
26. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. 2009. HPV screening for cervical cancer in rural India. N Engl J Med 360: 1385- 1394.
27. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286: 3106- 3114.
28. Soderlund-Strand A, Eklund C, Kemetli L, Grillner L, Tornberg S, Dillner J, Dillner L. 2011. Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol 205: 145.e1-6.
29. Tamalet C, Richet H, Carcopino X, Henry M, Leretraite L, Heid P, Leandri FX, Sancho-Garnier H, Piana L. 2010. Testing for Human Papillomavirus and measurement of viral load of HPV 16 and 18 in self-collected vaginal swabs of women who do not undergo cervical cytological screening in southern France. J Med Virol 82: 1431- 1437.
30. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12- 19.
31. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. 2001. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357: 1831- 1836.
32. Xi LF, Hughes JP, Edelstein ZR, Kiviat NB, Koutsky LA, Mao C, Ho J, Schiffman M. 2009. Human papillomavirus (HPV) type 16 and type 18 DNA loads at baseline and persistence of type-specific infection during a 2-year follow-up. J Infect Dis 200: 1789- 1797.
33. Xi LF, Hughes JP, Castle PE, Edelstein ZR, Wang C, Galloway DA, Koutsky LA, Kiviat NB, Schiffman M. 2011. Viral load in the natural history of human papillomavirus type 16 infection: A nested case-control study. J Infect Dis 203: 1425- 1433.
34. zur Hausen H. 2002. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev 2: 342- 350.
35. zur Hausen H. 2009. The search for infectious causes of human cancers: Where and why (Nobel lecture). Angewandte Chemie Int ed 48: 5798- 5808.